ReviewInternational journal of molecular sciences2019
Novel Therapeutic Potentials of Taxifolin for Amyloid-β-associated Neurodegenerative Diseases and Other Diseases: Recent Advances and Future Perspectives.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Cadmium-induced apoptosis via ROS/JNK pathway in chicken primary kidney cells and antagonism of taxifolin.Poultry science · 2026Article
- A Nose-to-Brain Delivery System for Taxifolin Ameliorates Alzheimer's Disease via Synergistic Attenuation of Oxidative Stress and Mitochondrial Dysfunction.Antioxidants (Basel, Switzerland) · 2026Article
- Shared molecular mechanisms in aging and neurodegenerative diseases: from mechanistic insights to therapeutic strategies.Frontiers in human neuroscience · 2026Review
- Exploring the therapeutic potential of naturally occurring taxifolin, a dietary flavonoid: an updated comprehensive review.Frontiers in pharmacology · 2026Review
- A facile and practical method for the synthesis ofBeilstein journal of organic chemistry · 2026Article
- Protective effects of taxifolin against oxidative stress and apoptosis in liver ischemia-reperfusion injury: an experimental animal study.Annals of surgical treatment and research · 2025Article
- Dihydroquercetin and Related Flavonoids in Antioxidant Formulations with α-Tocopherol.International journal of molecular sciences · 2025Article
- Plant-Based Inhibitors of Protein Aggregation.Biomolecules · 2025Review
- Case Report: Taxifolin for neurosurgery-associated early-onset cerebral amyloid angiopathy.Frontiers in neurology · 2024Article
- Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.Journal of experimental & clinical cancer research : CR · 2023Article
- Anti-Amnesia-like Effect ofInternational journal of molecular sciences · 2023Article
- Protective Properties of Spheroidal Taxifolin Form in Streptozotocin-Induced Diabetic Rats.International journal of molecular sciences · 2023Article
- Taxifolin Suppresses Inflammatory Responses of High-Glucose-Stimulated Mouse Microglia by Attenuating the TXNIP-NLRP3 Axis.Nutrients · 2023Article
- Role of polyphenolic compounds and their nanoformulations: a comprehensive review on cross-talk between chronic kidney and cardiovascular diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- New Perspectives of Taxifolin in Neurodegenerative Diseases.Current neuropharmacology · 2023Review
- Hepatoprotective and neuroprotective effect of taxifolin on hepatic encephalopathy in rats.Metabolic brain disease · 2022Article
- Antidiabetic Effect of Taxifolin in Cultured L6 Myotubes and Type 2 Diabetic Model KK-ACurrent issues in molecular biology · 2021Article
- Conifers Phytochemicals: A Valuable Forest with Therapeutic Potential.Molecules (Basel, Switzerland) · 2021Review
- Remodeling the Epigenetic Landscape of Cancer-Application Potential of Flavonoids in the Prevention and Treatment of Cancer.Frontiers in oncology · 2021Review
- Taxifolin: A Potential Therapeutic Agent for Cerebral Amyloid Angiopathy.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Amyloid-β (Aβ) has been closely implicated in the pathogenesis of cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD), the major causes of dementia. Thus, Aβ could be a target for the treatment of these diseases, for which, currently, there are no established effective treatments. Taxifolin is a bioactive catechol-type flavonoid present in various plants, such as herbs, and it exhibits pleiotropic effects including anti-oxidant and anti-glycation activities. Recently, we have demonstrated that taxifolin inhibits Aβ fibril formation in vitro and have further shown that it improves cerebral blood flow, facilitating Aβ clearance in the brain and suppressing cognitive decline in a mouse model of CAA. These findings suggest the novel therapeutic potentials of taxifolin for CAA. Furthermore, recent extensive studies have reported several novel aspects of taxifolin supporting its potential as a therapeutic drug for AD and metabolic diseases with a high risk for dementia as well as for CAA. In this review, we have summarized the recent advances in taxifolin research based on in vitro, in vivo, and in silico approaches. Furthermore, we have discussed future research directions on the potential of taxifolin for use in novel therapeutic strategies for CAA, AD, and metabolic diseases with an increased risk for dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.